Algert Global LLC Morphic Holding, Inc. Transaction History

Algert Global LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$26.12 - $34.07 $431,789 - $563,211	16,531 Added 99.72%	33,108 $1.13 Million
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $330,711 - $513,887	16,577 New	16,577 $479,000
Q2 2023 Aug 14, 2023	SELL	$34.33 - $62.11 $1.06 Million - $1.92 Million	-30,890 Reduced 57.27%	23,046 $1.32 Million
Q1 2023 May 12, 2023	SELL	$26.01 - $48.69 $638,337 - $1.19 Million	-24,542 Reduced 31.27%	53,936 $2.03 Million
Q4 2022 Feb 13, 2023	BUY	$24.14 - $30.37 $1.89 Million - $2.38 Million	78,478 New	78,478 $2.1 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.